[REVISION HISTORY]

Advancements in Alzheimer's detection, AI, and drug access

26 recorded revisions of this situation.

What changed

2026-09-25 19:41 UTC → 2026-10-09 19:00 UTC · added ~~removed~~

Research into Alzheimer's biomarkers continues to evolve, with recent findings refining the utility of blood-based testing. While plasma p-tau217 remains a key indicator, studies suggest its predictive power in symptom-free individuals is moderate compared to its high accuracy during the clinical stage. New data indicates that healthy older adults with high levels of p-tau217 have a one-in-three chance of developing memory impairment within five years and a nearly 80% chance within ten years. In the United States, the FDA has cleared several blood tests to assist in identifying amyloid and tau biomarkers, including Roche’s Elecsys pTau217, the Lumipulse test, and C2N Diagnostics’ PrecivityAD2. Artificial intelligence is also being utilized to analyze blood plasma protein ratios, MRI scans, retinal changes, and speech patterns to enhance diagnostic accuracy. Clinical practices are increasingly shifting toward these blood-based biomarkers to diagnose the disease significantly earlier than traditional symptom-based methods. In Spain, health authorities in Andalucía and institutions like HCB Hospitales are integrating these less invasive tests into specialized practice. Global health experts emphasize early diagnosis to maximize the effectiveness of emerging anti-amyloid therapies, such as donanemab and lecanemab, which can reduce the risk of clinical progression by 30-50%. Recent developments suggest blood biomarkers may also play a role in treatment monitoring. Researchers at the Washington University School of Medicine identified dozens of blood proteins that change during treatment with lecanemab. This study suggests that these biomarkers could eventually allow clinicians to monitor treatment efficacy through blood tests rather than relying solely on expensive brain scans, providing a more accessible way to track how individual patients respond to medication. Additionally, genetic testing is being used to identify specific pathogenic variations, such as mutations in the Presenilin 1 (PSEN1) gene, which are linked to certain early-onset cases where disease onset is certain.

Versions

Select a version to see what changed compared to the one before it.